These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27364904)

  • 1. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
    Miller RE; Brough R; Bajrami I; Williamson CT; McDade S; Campbell J; Kigozi A; Rafiq R; Pemberton H; Natrajan R; Joel J; Astley H; Mahoney C; Moore JD; Torrance C; Gordan JD; Webber JT; Levin RS; Shokat KM; Bandyopadhyay S; Lord CJ; Ashworth A
    Mol Cancer Ther; 2016 Jul; 15(7):1472-84. PubMed ID: 27364904
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Kawahara N; Yamada Y; Kobayashi H
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Kuroda T; Ogiwara H; Sasaki M; Takahashi K; Yoshida H; Kiyokawa T; Sudo K; Tamura K; Kato T; Okamoto A; Kohno T
    Gynecol Oncol; 2019 Dec; 155(3):489-498. PubMed ID: 31604667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
    Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
    Kim M; Lu F; Zhang Y
    Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors.
    Berns K; Caumanns JJ; Hijmans EM; Gennissen AMC; Severson TM; Evers B; Wisman GBA; Jan Meersma G; Lieftink C; Beijersbergen RL; Itamochi H; van der Zee AGJ; de Jong S; Bernards R
    Oncogene; 2018 Aug; 37(33):4611-4625. PubMed ID: 29760405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the IRE1α/XBP1 Endoplasmic Reticulum Stress Response Pathway in
    Zundell JA; Fukumoto T; Lin J; Fatkhudinov N; Nacarelli T; Kossenkov AV; Liu Q; Cassel J; Hu CA; Wu S; Zhang R
    Cancer Res; 2021 Oct; 81(20):5325-5335. PubMed ID: 34548333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma.
    Li S; Meersma GJ; Kupryjanczyk J; de Jong S; Wisman GBA
    J Transl Med; 2024 Jun; 22(1):556. PubMed ID: 38858765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries.
    Zhang X; Shetty M; Clemente V; Linder S; Bazzaro M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33947138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
    Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
    Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
    [No Abstract]   [Full Text] [Related]  

  • 11. Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling.
    Chandler RL; Damrauer JS; Raab JR; Schisler JC; Wilkerson MD; Didion JP; Starmer J; Serber D; Yee D; Xiong J; Darr DB; Pardo-Manuel de Villena F; Kim WY; Magnuson T
    Nat Commun; 2015 Jan; 6():6118. PubMed ID: 25625625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precision medicine for ovarian clear cell carcinoma based on gene alterations.
    Kuroda T; Kohno T
    Int J Clin Oncol; 2020 Mar; 25(3):419-424. PubMed ID: 32020380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA GAS5 inhibits the proliferation and invasion of ovarian clear cell carcinoma via the miR-31-5p/ARID1A axis.
    Zhang J; Yang ZM; Huang Y; Wang KN; Xie Y; Yang N
    Kaohsiung J Med Sci; 2021 Nov; 37(11):940-950. PubMed ID: 34414664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of ARID1A associated with decreased CD8 T cells improves cell survival of ovarian clear cell carcinoma.
    Jung US; Min KW; Kim DH; Kwon MJ; Park H; Jang HS
    J Gynecol Oncol; 2021 Jan; 32(1):e3. PubMed ID: 33185044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARID1A mutations in endometriosis-associated ovarian carcinomas.
    Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
    N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma.
    Katagiri A; Nakayama K; Rahman MT; Rahman M; Katagiri H; Nakayama N; Ishikawa M; Ishibashi T; Iida K; Kobayashi H; Otsuki Y; Nakayama S; Miyazaki K
    Mod Pathol; 2012 Feb; 25(2):282-8. PubMed ID: 22101352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
    Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
    Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma.
    Takai M; Nakagawa T; Tanabe A; Terai Y; Ohmichi M; Asahi M
    Cancer Biol Ther; 2015; 16(2):325-35. PubMed ID: 25756515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
    Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
    Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.